Handelsinvest Investeringsforvaltning’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Handelsinvest Investeringsforvaltning’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-45,000	Closed	-$5.34M	–	112
2022 Q1	$5.34M	Sell	45,000 -5,000	-10%	-$624K	0.65%	55
2021 Q4	$6.89M	Hold	50,000	–	–	0.7%	54
2021 Q3	$6.95M	Hold	50,000	–	–	0.76%	57
2021 Q2	$4.85M	Hold	50,000	–	–	0.54%	76
2021 Q1	$3.42M	Buy	50,000 +5,000	+11%	+$404K	0.42%	90
2020 Q4	$3.86M	Buy	45,000 +5,000	+13%	+$424K	0.57%	70
2020 Q3	$2.6M	Hold	40,000	–	–	0.49%	63
2020 Q2	$2.92M	Hold	40,000	–	–	0.61%	56
2020 Q1	$1.36M	Hold	40,000	–	–	0.36%	71
2019 Q4	$2.18M	Hold	40,000	–	–	0.43%	66
2019 Q3	$1.67M	Buy	40,000 +20,000	+100%	+$845K	0.37%	61
2019 Q2	$876K	Buy	+20,000	New	+$1.13M	0.18%	90

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Handelsinvest Investeringsforvaltning's BHVN Position: Q2 2022 in Review

Handelsinvest Investeringsforvaltning sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 45,000 shares — an estimated $5.34M sold.

Handelsinvest Investeringsforvaltning first reported a position in BHVN in Q2 2019 and held it in 12 quarters. The position peaked at $6.95M in Q3 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Handelsinvest Investeringsforvaltning reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Handelsinvest Investeringsforvaltning sold 45,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $5.34M.
Handelsinvest Investeringsforvaltning first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 12 quarters.
Handelsinvest Investeringsforvaltning's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $6.95M in Q3 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Handelsinvest Investeringsforvaltning's 13F filing for Q2 2022, filed 13 Jul 2022.